Podocyte injury and death:New insights into lupus nephritis pathogenesis and therapy  

作　　者：Xiaolei Shi Zhipeng Wang Ruihan Tang Wei Chen 

机构地区：[1]Department of Nephrology,The First Affiliated Hospital,Sun Yat-sen University,Guangdong,Guangzhou,China [2]Key Laboratory of Nephrology,National Health Commission of China,Guangdong,China [3]Key Laboratory of Nephrology,Guangdong Provincial,Guangzhou,China

出　　处：《Rheumatology & Autoimmunity》2023年第4期193-204,共12页风湿病与自身免疫（英文）

基　　金：Key Laboratory of National Health Commission,and Key Laboratory of Nephrology,Guangdong Province,Guangzhou,China,Grant/Award Numbers:2002B60118,2020B1212060028;National Natural Science Foundation of China,Grant/Award Numbers:81970599,82170737。

摘　　要：Lupus nephritis(LN),an immune complex-mediated glomerulonephritis,is one of the most severe complications of systemic lupus erythematosus.Current therapeutic regimens for LN mainly involve nonspecific immunosuppressants and biologics targeting immune cells,but these treatments are not always effective and some patients are nonresponsive and susceptible to recurrence.Podocytes are essential for maintaining the glomerular filtration barrier.Injury to and loss of podocytes lead to proteinuria,a hallmark of renal involvement and LN.Podocytes are,therefore,emerging as prospective therapeutic targets for LN.There are numerous mechanisms underlying podocyte malfunction in LN,with autophagy,mitochondrial dysregulation,and programmed cell death being the main processes behind podocyte loss.This review summarizes recent advances in understanding podocyte dysfunction in LN pathogenesis and discusses potential therapeutic interventions targeting podocytes in LN.

关 键 词：cell death INJURY lupus nephritis PODOCYTE treatment 

分 类 号：R593.24[医药卫生—内科学]